Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
10.51
+0.10 (0.96%)
At close: Mar 11, 2025, 4:00 PM
10.67
+0.16 (1.52%)
After-hours: Mar 11, 2025, 5:22 PM EST
Aligos Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Aligos Therapeutics stock has a target of 70, which predicts an increase of 566.03% from the current stock price of 10.51.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Aligos Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $70 | Strong Buy | Maintains | $75 → $70 | +566.03% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +613.61% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +613.61% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +613.61% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $75 | Strong Buy | Initiates | $75 | +613.61% | Aug 19, 2024 |
Financial Forecast
Revenue This Year
1.36M
from 3.95M
Decreased by -65.53%
Revenue Next Year
n/a
from 1.36M
EPS This Year
-12.16
from -20.94
EPS Next Year
-13.40
from -12.16
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.2M | n/a | n/a | ||
| Avg | 1.4M | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.5% | - | - | ||
| Avg | -65.5% | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -8.54 | -7.16 | -7.95 | ||
| Avg | -12.16 | -13.40 | -15.99 | ||
| Low | -17.52 | -19.07 | -23.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.